Background: Current antiretroviral treatment can induce significant and sustained virological and immunological responses in HIV-1-infected persons over at least the short- to mid-term. Objectives: In this study, long-term immune reconstitution was investigated during highly active antiretroviral therapy. Methods: Patients enrolled in the INCAS study in The Netherlands were treated for 102 weeks (range 52-144 weeks) with nevirapine (NVP) + zidovudine (ZDV) (n = 9), didanosine (ddl) + ZDV (n 10), or NVP + ddl + ZDV (n = 10). Memory and naive CD4+ and CD8+ T cells were measured using CD45RA and CD27 monoclonal antibodies (mAb), T-cell function was assayed by CD3 + CD28 mAb stimulation, and plasma HIV-1 RNA load was measured by ultra-direct as...
BACKGROUND: The extent of short-term CD4(+) T-cell recovery in patients tolerating first-line highly...
Background: Control of HIV replication can be observed in highly active antiretroviral therapy (HAAR...
International audienceBackground: Antiretroviral combination therapy raises issues of long-term adhe...
Background: Current antiretroviral treatment can induce significant and sustained virological and im...
Today's antiretroviral combination regimens can induce significant and sustained decreases in human ...
Objectives. To define the level of pathogen-specific immune reconstitution persisting over 3 to 5 ye...
BACKGROUND: Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV)-1 in...
BACKGROUND: A small but significant number of patients do not achieve CD4 T-cell counts >500 cells/µ...
BACKGROUND: The long-term immunological benefit of protease inhibitor (PI)-sparing antiretroviral th...
BACKGROUND: In recent years, treatment options for human immunodeficiency virus type 1 (HIV-1) infec...
Background: The extent of short-term CD4+ T-cell recovery in patients tolerating first-line highly a...
Introduction: Data on patients with long-term exposure to ART is scarce because controlled studies u...
The effects of 1 year of zidovudine, lamivudine, and ritonavir treatment on immune re-constitution w...
The very first HIV-1 infected patients who received antiretroviral combination therapy (HAART) were ...
BACKGROUND: CD4+ T-cell recovery in patients with continuous suppression of plasma HIV-1 viral load ...
BACKGROUND: The extent of short-term CD4(+) T-cell recovery in patients tolerating first-line highly...
Background: Control of HIV replication can be observed in highly active antiretroviral therapy (HAAR...
International audienceBackground: Antiretroviral combination therapy raises issues of long-term adhe...
Background: Current antiretroviral treatment can induce significant and sustained virological and im...
Today's antiretroviral combination regimens can induce significant and sustained decreases in human ...
Objectives. To define the level of pathogen-specific immune reconstitution persisting over 3 to 5 ye...
BACKGROUND: Highly active antiretroviral therapy (HAART) for human immunodeficiency virus (HIV)-1 in...
BACKGROUND: A small but significant number of patients do not achieve CD4 T-cell counts >500 cells/µ...
BACKGROUND: The long-term immunological benefit of protease inhibitor (PI)-sparing antiretroviral th...
BACKGROUND: In recent years, treatment options for human immunodeficiency virus type 1 (HIV-1) infec...
Background: The extent of short-term CD4+ T-cell recovery in patients tolerating first-line highly a...
Introduction: Data on patients with long-term exposure to ART is scarce because controlled studies u...
The effects of 1 year of zidovudine, lamivudine, and ritonavir treatment on immune re-constitution w...
The very first HIV-1 infected patients who received antiretroviral combination therapy (HAART) were ...
BACKGROUND: CD4+ T-cell recovery in patients with continuous suppression of plasma HIV-1 viral load ...
BACKGROUND: The extent of short-term CD4(+) T-cell recovery in patients tolerating first-line highly...
Background: Control of HIV replication can be observed in highly active antiretroviral therapy (HAAR...
International audienceBackground: Antiretroviral combination therapy raises issues of long-term adhe...